Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Frontage Holdings Corporation (FGHQF)
Exton, PA, US
Frontage Holdings Corporation operates as a contract research organization, furnishing an extensive array of laboratory and associated services to pharmaceutical, biotechnology, and agrochemical firms, in addition to conducting bioequivalence studies. Its service portfolio includes laboratory testing, covering method development, validation, sample analysis, and central laboratory functions. The company also delivers chemistry, manufacturing, and control (CMC) services, which involve assisting with drug product development and analysis, alongside the provision and supply of materials for clinical trials. Furthermore, Frontage offers drug metabolism and pharmacokinetic (DMPK) services, encompassing study design, execution, and data interpretation, from early discovery structural optimization to pharmacokinetic assessments in rodents and non-GLP bioanalytical studies. Its expertise extends to safety and toxicology, performed through both in-vitro and in-vivo studies. The company also handles bioequivalence services, managing their design, coordination, and reporting, as well as general chemistry services like contract research and custom synthesis. Lastly, clinical services are provided, including early-stage trials, bioequivalence/bioavailability (BE/BA) studies, biometrics, and data management. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage maintains a global presence, operating in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. It functions as a subsidiary of Hongkong Tigermed Co., Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +7.14% | +0.13% | +0.13% | +48.51% | -54.07% | -69.39% | -69.39% | -69.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+0.9% Q4'25: -1.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+750.0% ★ Q4'25: -36.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+6.8% ★ Q4'25: +11.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+5.7% ★ Q4'25: +5.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+2.0% ★ Q4'25: +4.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q4'25: -2.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.58× Q4'25: 1.30× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
100.97M
est: 109.73M (-8.0%)
|
125.85M
est: 123.78M (+1.7%)
|
183.83M
est: 186.46M (-1.4%)
|
250.96M
est: 254.58M (-1.4%)
|
259.86M
est: 270.48M (-3.9%)
|
254.91M
est: 270.14M (-5.6%)
|
257.07M
est: 256.14M (+0.4%)
|
285.78M
278.57M – 292.98M
+11.6% YoY
|
312.14M
303.63M – 320.66M
+9.2% YoY
|
330.61M
321.92M – 339.29M
+5.9% YoY
|
| EBITDA |
29.77M
est: 27.34M (+8.9%)
|
34.05M
est: 30.84M (+10.4%)
|
51.56M
est: 46.45M (+11.0%)
|
69.91M
est: 63.42M (+10.2%)
|
57.22M
est: 67.38M (-15.1%)
|
49.93M
est: 63.09M (-20.9%)
|
49.53M
est: 59.82M (-17.2%)
|
66.74M
65.06M – 68.43M
+11.6% YoY
|
72.90M
70.91M – 74.89M
+9.2% YoY
|
77.21M
75.18M – 79.24M
+5.9% YoY
|
| EBIT |
22.22M
est: 13.47M (+65.0%)
|
21.79M
est: 15.19M (+43.4%)
|
27.55M
est: 22.89M (+20.4%)
|
40.04M
est: 31.25M (+28.2%)
|
21.65M
est: 33.20M (-34.8%)
|
12.31M
est: 26.90M (-54.2%)
|
14.58M
est: 25.51M (-42.8%)
|
28.46M
27.74M – 29.17M
+11.6% YoY
|
31.08M
30.23M – 31.93M
+9.2% YoY
|
32.92M
32.06M – 33.79M
+5.9% YoY
|
| Net Income |
18.42M
est: 21.07M (-12.6%)
|
17.15M
est: 17.88M (-4.1%)
|
18.43M
est: 27.41M (-32.8%)
|
25.74M
est: 29.42M (-12.5%)
|
10.81M
est: 27.06M (-60.1%)
|
791.0K
est: 14.69M (-94.6%)
|
6.80M
est: 8.06M (-15.6%)
|
8.97M
8.66M – 9.28M
+11.3% YoY
|
20.05M
19.37M – 20.74M
+123.6% YoY
|
20.28M
19.59M – 20.97M
+1.1% YoY
|
| SGA |
21.80M
est: 22.58M (-3.5%)
|
23.98M
est: 25.47M (-5.9%)
|
38.96M
est: 38.37M (+1.5%)
|
51.63M
est: 52.39M (-1.5%)
|
52.73M
est: 55.66M (-5.3%)
|
55.54M
est: 55.89M (-0.6%)
|
50.41M
est: 53.00M (-4.9%)
|
59.13M
57.64M – 60.62M
+11.6% YoY
|
64.59M
62.83M – 66.35M
+9.2% YoY
|
68.41M
66.61M – 70.20M
+5.9% YoY
|
| EPS |
0.01
est: 0.01 (-0.7%)
|
0.01
est: 0.01 (-3.4%)
|
0.01
est: 0.01 (-33.3%)
|
0.01
est: 0.01 (-13.0%)
|
0.01
est: 0.01 (-60.2%)
|
0.00
est: 0.01 (-94.5%)
|
0.00
est: 0.00 (-14.5%)
|
0.00
0.00 – 0.00
+11.3% YoY
|
0.01
0.01 – 0.01
+123.6% YoY
|
0.01
0.01 – 0.01
+1.1% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhongping Lin | Co-CEO Executive & Director | 798.0K | — |
| Wentao Zhang | Co-CEO & Executive Director | 771.0K | — |
| Abdul Ezaz Mutlib | Chief Scientific & Strategy Officer and President of Frontage Laboratories of Canada | 691.0K | — |
| Song Li | Founder & Chairman | 368.0K | — |
| Richard Fischetti | Vice President & General Counsel of Frontage Labs | — | male |
| John Kapeghian | Executive Vice President of Global Safety & Toxicology | — | — |
| Tianyi Zhang | Senior Vice President of the Group & GM of Frontage Shanghai | — | — |
| Huan Wang | Interim Chief Financial Officer | — | female |
| Dongmei Wang | Executive Vice President of Global Sales & Marketing | — | — |
| Sudendra Rao | Senior Vice President of Human Resources - North America | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FGHQF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
